Special Collaborations
What it is.
The Leukemia & Lymphoma Society has special collaborations with foundations and individual researchers in order to accelerate research, stimulate innovation and solve disease-specific challenges.
What it does.
LLS has significant collaborations with organizations, including The Rising Tide Foundation for Clinical Cancer Research (RTFCCR), through which we are jointly supporting immunotherapy projects; The Babich Family Foundation, seeking to support research in the RUNX1 mutation in AML; The MPN Research Foundation; The International Waldenstrom’s Macroglobulinemia Foundation (IWMF); The Hairy Cell Leukemia Foundation and The Sass Foundation for Medical Research.
Marie Bleakley PhD, MD
Fred Hutchinson Cancer Research Center
"Funding from the MPN Challenge Grant will allow us to investigate how T cells can specifically kill MPN stem cells through MPN mutations. T cell receptor based immunotherapies targeting recurrent MPN-associated mutations offer the possibility of curing these diseases without stem cell transplantation and its associated toxicities. Used early enough in the disease course, immunotherapies could save lives."
Ann Leen, Ph.D.
Baylor College of Medicine
"I am delighted to be an RTFCCC/LLS Patient-Focused Immunotherapy Grant Award recipient. My overarching goal is to improve outcomes in patients with acute myeloid leukemia and this grant will allow me to test the clinical benefit of a T-cell therapy, which I truly believe has transformative potential, in patients who have failed conventional approaches."
Ronald Levy, M.D.
Stanford University
"We are hoping to develop a new way of triggering the immune system to treat cancer. The RTFCCC/LLS Patient-Focused Immunotherapy Grant Award will help us to understand how injecting immune stimulating molecules directly into one site of tumor will alter the microenvironment and trigger an immune response against the lymphoma throughout the body."
FY19 Grant Recipients
International Waldenstrom's Macroglobulinemia Foundation
Sherine Elsawa, PhD
University of New Hampshire
Epigenetic Regulation of WM Biology
Zachary Hunter, PhD
Dana-Farber Cancer Institute
Transcriptional Characterization of Untreated Patients with Waldenström’s Macroglobulinemia
MPN Research Foundation
Angela Fleischman, MD, PhD
The Regents of the University of California, Irvine
Inflammation as a driver of clonal expansion in myeloproliferative neoplasm
James Griffin, MD
Dana-Farber Cancer Institute
Inhibition of deubiquitinating enzymes as a novel targeted therapy for JAK2-dependent myeloid malignancies
Vivian Oehler, MD
Fred Hutchinson Cancer Research Center
Characterizing myeloproliferative neoplasm neoantigens and T Cell responses for therapeutic applications
Stephen Oh, MD, PhD
Washington University in St. Louis
Leveraging NFKB pathway dysregulation for therapeutic benefit in Myeloproliferative Neoplasms
Rebekka K Schneider, MD
Erasmus University Rotterdam
Functional and molecular dissection of the fibrotic transformation and clonal selection in myeloproliferative neoplasms
Rising Tide Foundation for Clinical Cancer Research
C. Ola Landgren, MD, PhD
Sloan Kettering Institute for Cancer Research
CD38-targeted immuno-PET imaging to detect early myeloma
George Vassiliou, PhD, MBBS
Wellcome Trust Sanger Institute
Prevention of myeloid cancers by understanding their pre-clinical evolution